3003新葡的京集团
Other Affiliated Sites
Techdow Pharma China
Techdow Pharma UK
Techdow Pharma Poland
Techdow Pharma Italy
Techdow Pharma Spain
Techdow Pharma Germany
Techdow Pharma US
Cytovance Biologics
SPL
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
Financial Reports
Announcements
2021.06.29
2020年年度权益分派实施公告
2021.06.28
深圳市3003新葡的京集团药业集团股份有限公司公司债券2020年定期受托管理事务报告
2021.06.28
深圳市3003新葡的京集团药业集团股份有限公司2016年公司债券受托管理事务年度报告(2020年度)
2021.06.24
H股公告
2021.06.11
H股公告
2021.06.10
关于第二期和第三期员工持股计划的提示性公告
2021.06.08
H股公告
2021.06.02
关于控股子公司收到药物临床试验补充申请批准通知书的公告
2021.05.27
2020年年度股东大会决议公告
2021.05.27
2020年年度股东大会法律意见书
第一页
上一页
20
21
22
23
24
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright © 2024 Hepalink Group. All Rights Reserved.